The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells.

[1]  S. Hanash,et al.  Linker for Activation of T-cell Family Member2 (LAT2) a Lipid Raft Adaptor Protein for AKT Signaling, Is an Early Mediator of Alkylphospholipid Anti-leukemic Activity* , 2012, Molecular & Cellular Proteomics.

[2]  T. Kalina,et al.  The adaptor protein NTAL enhances proximal signaling and potentiates corticosteroid-induced apoptosis in T-ALL. , 2012, Experimental hematology.

[3]  Salam A. Assi,et al.  Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding , 2012, Leukemia.

[4]  M. Lübbert,et al.  The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO , 2011, Oncogene.

[5]  M. Lübbert,et al.  Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation , 2011, British journal of haematology.

[6]  B. Hackanson1,et al.  Epigenetische Modifikationen in malignen Zellen , 2011 .

[7]  Selinda J Orr,et al.  LAB/NTAL/Lat2: a force to be reckoned with in all leukocytes? , 2011, Journal of leukocyte biology.

[8]  O. Abdel-Wahab,et al.  Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. , 2010, Blood.

[9]  M. Loh,et al.  Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia , 2010, Nature Genetics.

[10]  John D. Minna,et al.  Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer , 2010 .

[11]  M. Loh,et al.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.

[12]  S. Ogawa,et al.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.

[13]  A. Migliaccio,et al.  NF‐E2 overexpression delays erythroid maturation and increases erythrocyte production , 2009, British journal of haematology.

[14]  M. Caligiuri,et al.  Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. , 2007, Blood.

[15]  Adelheid Cerwenka,et al.  Non-T Cell Activation Linker (NTAL) Negatively Regulates TREM-1/DAP12-Induced Inflammatory Cytokine Production in Myeloid Cells1 , 2007, The Journal of Immunology.

[16]  T. Denning,et al.  Negative regulation of T cell activation and autoimmunity by the transmembrane adaptor protein LAB. , 2006, Immunity.

[17]  M. Lübbert,et al.  Williams–Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO , 2004, Oncogene.

[18]  A. Satterthwaite,et al.  NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. , 2004, Blood.

[19]  T. Kitamura,et al.  Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. , 2003, Experimental hematology.

[20]  Weijia Zhang,et al.  LAB: A new membrane-associated adaptor molecule in B cell activation , 2003, Nature Immunology.

[21]  L. Lanier.  Faculty Opinions recommendation of Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling. , 2003 .

[22]  Nanxin Li,et al.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein , 1993, Cell.

[23]  Rowley Jd.  Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. , 1973 .

[24]  M. Lübbert,et al.  [Epigenetic changes in malignant cells]. , 2011, Deutsche Medizinische Wochenschrift.

[25]  Y. Natkunam,et al.  Transmembrane adaptor molecules: a new category of lymphoid-cell markers. , 2006, Blood.

[26]  Andrea Richardson,et al.  A role for the scaffolding adapter GAB2 in breast cancer , 2006, Nature Medicine.